Nancy Allbritton,
Frank and Julie Jungers Dean of the College of Engineering and Professor of Bioengineering,
University of Washington in Seattle
Nancy L. Allbritton is the Frank and Julie Jungers Dean of the College of Engineering and Professor of Bioengineering at the University of Washington in Seattle.
Her research focuses on the development of novel technologies for applications in single-cell analysis, micro-arrays and fluidics, and organ-on-chip and has resulted in over 180 full-length journal publications and patents and led to 15 commercial products. Her research program has been well funded by the National Institutes of Health with $60 million in grant funding since 1994. Four companies have been formed based on her research discoveries: Protein Simple (acquired by Bio-Techne in 2014 for $308M), Intellego (subsequently integrated into International Rectifier), Cell Microsystems (www.cellmicrosystems.com), and Altis Biosystems (www.altisbiosystems.com). Dr. Allbritton is a Fellow of the American Association for the Advancement of Science, the American Institute for Medical & Biological Engineering, and the National Academy of Inventors. She obtained her B.S. in physics from Louisiana State University, M.D. from Johns Hopkins University, and Ph.D. in Medical Physics/Medical Engineering from the Massachusetts Institute of Technology, with a postdoctoral fellowship at Stanford University.
Microraft Array Platform for the Selection of Lymphocytes Based on Target-Cell Killing
Tuesday, 27 September 2016 at 13:30
Add to Calendar ▼2016-09-28 14:00:002016-09-28 15:00:00Europe/LondonMicroraft Array Platform for the Selection of Lymphocytes Based on Target-Cell KillingLab-on-a-Chip, Microfluidics and Microarrays World Congress 2016 in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com
Adoptive cellular therapy (ACT) is an emerging therapeutic in which
cytotoxic T lymphocytes (CTLs) that recognize tumor cell epitopes are
introduced into patients providing immunity against the cancer cells.
For ACT to succeed, CTLs with high tumor-killing efficiency must be
identified, isolated, and characterized. Current technologies do not
enable simultaneous assay of cell behavior or killing followed by
recovery of the most efficient killer cells. A microraft array
technology that measures the ability of individual T cells to lyse a
population of target cells followed by sorting of living cells into a
multi-well plate for expansion and characterization was developed. The
microraft array platform was combined with image processing and analysis
algorithms to track and monitor killing assays over many hours.
Automated cell collection was incorporated into the platform for facile
cell collection from the array. As a proof of principle, human T cells
directed against an influenza antigen were co-cultured with antigen
presenting target cells on the microraft arrays. Target cell killing was
measured by tracking the appearance of dead cells on each microraft
over time. Microrafts with a single CTL demonstrating the greatest rate
of target cell death were identified, cloned, and influenza-antigen
reactivity confirmed. The platform is readily modified to measure the
antigen-specific activity of individual cells within a bulk CTL culture
or the cell heterogeneity within a population of gene-engineered T
cells.
Add to Calendar ▼2016-09-26 00:00:002016-09-28 00:00:00Europe/LondonLab-on-a-Chip, Microfluidics and Microarrays World Congress 2016Lab-on-a-Chip, Microfluidics and Microarrays World Congress 2016 in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2016-09-28 14:00:002016-09-28 15:00:00Europe/LondonMicroraft Array Platform for the Selection of Lymphocytes Based on Target-Cell KillingLab-on-a-Chip, Microfluidics and Microarrays World Congress 2016 in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com
